Breaking News Instant updates and real-time market news.

REGN

Regeneron

$404.03

13.87 (3.56%)

13:05
08/29/18
08/29
13:05
08/29/18
13:05

Regeneron call volume above normal and directionally bullish

Bullish option flow detected in Regeneron with 5,388 calls trading, 3x expected, and implied vol increasing almost 2 points to 27.10%. 8/31 weekly 400 calls and Jan-19 380 puts are the most active options, with total volume in those strikes near 1,500 contracts. The Put/Call Ratio is 0.34. Earnings are expected on November 8th.

  • 12

    Sep

  • 20

    Oct

  • 28

    Oct

REGN Regeneron
$404.03

13.87 (3.56%)

08/16/18
PIPR
08/16/18
NO CHANGE
Target $450
PIPR
Overweight
Regeneron's fasinumab safety remains 'open question,' says Piper Jaffray
Piper Jaffray analyst Christopher Raymond backed an Overweight rating on Regeneron Pharmaceuticals (REGN) shares following this morning's release of fasinumab results, saying the drug and partner Teva's (TEVA) anti-NGF antibody met its primary and secondary efficacy pain and functional endpoints in a Phase 3 trial of patients with chronic pain from osteoarthritis of the knee or hip. Raymond says the efficacy "was never really in doubt," but the bigger focus for the drug is safety, and will wait for detailed data at an upcoming medical meeting, but notes that fasinumab's arthropathy rate appears "slightly higher" than that of tanezumab. Given the severity of the ongoing opioid epidemic and relative lack of alternatives for these patients outside of total joint replacement, the analyst thinks the appetite of regulators and potential market for new effective, non-opioid chronic pain therapies like anti-NGF clearly exists, though he will leave this as an unmodeled potential source of upside for now,
08/13/18
PIPR
08/13/18
NO CHANGE
PIPR
Overweight
Regeneron should be bought on 'largely meaningless' CRL, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond recommends buying shares of Regeneron Pharmaceuticals on weakness after the company received a Complete Response Letter from the FDA regarding Eylea's supplemental Biologics License Application for Q12W dosing in wet macular degeneration. The CRL is "largely meaningless" as this label expansion is almost entirely a defensive move by Regeneron to counter potential Q12W labeling by competitor Novartis' (NVS) RTH258, Raymond tells investors in a research note. The analyst has "reasonable confidence" that approval for this label will come within two months. He keeps an Overweight rating on shares of Regeneron.
08/08/18
PIPR
08/08/18
NO CHANGE
PIPR
Overweight
Piper says CMS Part B headlines 'scary,' but Regeneron pullback an overreaction
Piper Jaffray analyst Christopher Raymond said he would be a buyer on weakness in shares of Regeneron after CMS announced new rules giving Medicare Advantage plans the option of implementing "step therapy" to introduce competition. He checked in with leading drug pricing and reimbursement experts, whose view is that this may drive discounting and competition between Eylea and Lucentis, much like what exists today with private pay plans. After speaking with management, Raymond estimates about 3.4% of 2019 Eylea revenue is at risk. Assuming Regeneron has to price at Eylea at a 30% discount translates to a roughly $40M revenue impact and a 36c, or 1.5%, hit to EPS in 2019, said Raymond, who called the 6% pullback in the stock an overreaction in light of those estimates. He maintains an Overweight rating on Regeneron shares.
08/08/18
LEER
08/08/18
NO CHANGE
LEER
Regeneron, Amgen most exposed to Medicare Part B changes, says Leerink
After the Centers for Medicare and Medicaid Services announced that Medicare Advantage plans will have the option in 2019 of applying step therapy for physician-administered and other Part B drugs for new patients, Leerink analyst Geoffrey Porges said the end goal is to create MA plan formularies that can be used as a tool to negotiate with pharmaceutical makers for lower drug prices. Among the stocks he covers, Porges identifies Regeneron (REGN) and Amgen (AMGN) as among those with the most exposure to increased competitive intensity in Part B. For Regeneron, he sees the news re-igniting speculation about the threat of biosimilars and substitution with compounded Avastin, while for Amgen the change means that preference for its growth factor products facing biosimilar competition is likely to be challenged, the analyst said. Regeneron shares are down 4.6% to $373.34 in morning trading, while Amgen is down 2.2% to $195.89.

TODAY'S FREE FLY STORIES

FATE

Fate Therapeutics

$14.02

0.67 (5.02%)

16:26
09/20/18
09/20
16:26
09/20/18
16:26
Syndicate
Fate Therapeutics $100M Spot Secondary; re-offered at $13.50 »

Jefferies, Piper Jaffray…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

  • 21

    Sep

TMDI

Titan Medical

$2.22

0.04 (1.83%)

16:25
09/20/18
09/20
16:25
09/20/18
16:25
Conference/Events
Titan Medical to host business news update and outlook conference call »

Conference call to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 20

    Sep

  • 27

    Nov

SRE

Sempra Energy

$114.32

0.025 (0.02%)

, ED

Consolidated Edison

$78.43

0.11 (0.14%)

16:22
09/20/18
09/20
16:22
09/20/18
16:22
Hot Stocks
Sempra Energy to sell U.S. solar assets to Consolidated Edison »

Sempra Energy (SRE)…

SRE

Sempra Energy

$114.32

0.025 (0.02%)

ED

Consolidated Edison

$78.43

0.11 (0.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Oct

  • 11

    Nov

GTN

Gray Television

$17.35

0.4 (2.36%)

16:21
09/20/18
09/20
16:21
09/20/18
16:21
Hot Stocks
Gray Television reaches agreement to renew all Gray NBC affiliations »

Gray Television has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

AMZN

Amazon.com

$1,944.26

17.99 (0.93%)

, WFC

Wells Fargo

$55.57

0.34 (0.62%)

16:21
09/20/18
09/20
16:21
09/20/18
16:21
General news
Fly Intel: Wall Street's top stories for Thursday »

Stocks opened in positive…

AMZN

Amazon.com

$1,944.26

17.99 (0.93%)

WFC

Wells Fargo

$55.57

0.34 (0.62%)

GE

General Electric

$12.47

-0.39 (-3.03%)

DIS

Disney

$111.62

1.74 (1.58%)

SKYAY

Sky

$0.00

(0.00%)

CMCSA

Comcast

$37.81

0.49 (1.31%)

CMCSK

Comcast

$0.00

(0.00%)

FOX

21st Century Fox

$44.20

-0.05 (-0.11%)

FOXA

21st Century Fox

$44.59

-0.01 (-0.02%)

UAA

Under Armour

$20.01

1.26 (6.72%)

UA

Under Armour

$18.16

0.88 (5.09%)

CRBP

Corbus Pharmaceuticals

$7.90

2.75 (53.40%)

FOLD

Amicus

$12.64

0.84 (7.12%)

SFIX

Stitch Fix

$41.65

-5.56 (-11.78%)

THO

Thor Industries

$91.77

-13.95 (-13.20%)

RHT

Red Hat

$134.06

-9.32 (-6.50%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 20

    Sep

  • 24

    Sep

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 27

    Sep

  • 01

    Oct

  • 01

    Oct

  • 21

    Oct

  • 24

    Oct

  • 25

    Oct

  • 27

    Nov

  • 12

    Apr

  • 13

    Jul

  • 15

    Oct

URG

UR-Energy

$0.93

0.0406 (4.58%)

16:21
09/20/18
09/20
16:21
09/20/18
16:21
Syndicate
UR-Energy files to sell common stock and warrants »

Cantor Fitzgerald &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

URG

UR-Energy

$0.93

0.0406 (4.58%)

16:20
09/20/18
09/20
16:20
09/20/18
16:20
Syndicate
UR-Energy files to sell common stock, warrants, no amount given »

Cantor Fitzgerald &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

16:20
09/20/18
09/20
16:20
09/20/18
16:20
Options
Closing CBOE SPX and VIX Index summary for September 20th »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PIR

Pier 1 Imports

$1.80

0.045 (2.56%)

16:18
09/20/18
09/20
16:18
09/20/18
16:18
Hot Stocks
Pier 1 Imports CEO says disappointing Q2 reflects 'execution challenges' »

CEO Alasdair James said:…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CULP

Culp, Inc.

$24.75

-0.1 (-0.40%)

16:18
09/20/18
09/20
16:18
09/20/18
16:18
Hot Stocks
Culp CEO Saxon to assume additional role of vice chairman »

Culp announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

ED

Consolidated Edison

$78.43

0.11 (0.14%)

16:17
09/20/18
09/20
16:17
09/20/18
16:17
Hot Stocks
Con Edison to acquire 981 MW of renewable electric production projects »

Consolidated Edison…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Nov

DOV

Dover

$89.36

0.94 (1.06%)

16:17
09/20/18
09/20
16:17
09/20/18
16:17
Hot Stocks
Pole/Zero awarded over $66M contract by U.S. Department of Defense »

Pole/Zero, part of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PIR

Pier 1 Imports

$1.80

0.045 (2.56%)

16:17
09/20/18
09/20
16:17
09/20/18
16:17
Hot Stocks
Pier 1 Imports discontinues FY19 guidance »

The company states:…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

16:17
09/20/18
09/20
16:17
09/20/18
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INDB

Independent Bank

$89.85

0.65 (0.73%)

, BHBK

Blue Hills Bancorp

$23.55

0.4 (1.73%)

16:16
09/20/18
09/20
16:16
09/20/18
16:16
Hot Stocks
Independent Bank, Blue Hills sign merger pact for Rockland to acquire BHB »

Independent Bank Corp.…

INDB

Independent Bank

$89.85

0.65 (0.73%)

BHBK

Blue Hills Bancorp

$23.55

0.4 (1.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PIR

Pier 1 Imports

$1.80

0.045 (2.56%)

16:16
09/20/18
09/20
16:16
09/20/18
16:16
Earnings
Pier 1 Imports reports preliminary Q2 EPS (64c)-(62c), consensus (55c) »

Reports Q2 prelim SSS…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOD

Gladstone

$19.01

0.28 (1.49%)

16:16
09/20/18
09/20
16:16
09/20/18
16:16
Hot Stocks
Gladstone acquires $8.3M property in Delaware, Ohio »

Gladstone Commercial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

16:16
09/20/18
09/20
16:16
09/20/18
16:16
Technical Analysis
NYSE market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MU

Micron

$46.03

0.98 (2.18%)

16:15
09/20/18
09/20
16:15
09/20/18
16:15
Hot Stocks
Micron appoints Mike Bokan SVP Worldwide Sales »

Micron Technology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 20

    Sep

  • 24

    Sep

  • 25

    Sep

16:15
09/20/18
09/20
16:15
09/20/18
16:15
General news
Breaking General news story  »

Week of 9/10 Money Supply…

16:15
09/20/18
09/20
16:15
09/20/18
16:15
General news
Breaking General news story  »

Week of 9/19 Fed Balance…

ADVM

Adverum Biotechnologies

$5.70

-0.15 (-2.56%)

16:14
09/20/18
09/20
16:14
09/20/18
16:14
Initiation
Adverum Biotechnologies initiated  »

Adverum Biotechnologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

GBL

GAMCO Investors

$26.00

0.44 (1.72%)

, GCP

GCP Applied Technologies

$26.25

0.25 (0.96%)

16:14
09/20/18
09/20
16:14
09/20/18
16:14
Hot Stocks
Breaking Hot Stocks news story on GAMCO Investors, GCP Applied Technologies »

Gabelli reports 5% stake…

GBL

GAMCO Investors

$26.00

0.44 (1.72%)

GCP

GCP Applied Technologies

$26.25

0.25 (0.96%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSLT

Castlight Health

$2.90

0.1 (3.57%)

16:13
09/20/18
09/20
16:13
09/20/18
16:13
Hot Stocks
Breaking Hot Stocks news story on Castlight Health »

Neil Gagnon reports 5.5%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UNFI

United Natural Foods

$33.87

0.575 (1.73%)

16:12
09/20/18
09/20
16:12
09/20/18
16:12
Hot Stocks
Breaking Hot Stocks news story on United Natural Foods »

United Natural Foods down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 28

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.